151 related articles for article (PubMed ID: 26269767)
1. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.
Bunni J; Shelley-Fraser G; Stevenson K; Oltean S; Salmon A; Harper SJ; Carter JG; Bates DO
Am J Cancer Res; 2015; 5(6):2083-9. PubMed ID: 26269767
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.
Hamdollah Zadeh MA; Amin EM; Hoareau-Aveilla C; Domingo E; Symonds KE; Ye X; Heesom KJ; Salmon A; D'Silva O; Betteridge KB; Williams AC; Kerr DJ; Salmon AH; Oltean S; Midgley RS; Ladomery MR; Harper SJ; Varey AH; Bates DO
Mol Oncol; 2015 Jan; 9(1):167-78. PubMed ID: 25224594
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.
Wimberger P; Gerber MJ; Pfisterer J; Erdmann K; Füssel S; Link T; du Bois A; Kommoss S; Heitz F; Sehouli J; Kimmig R; de Gregorio N; Schmalfeldt B; Park-Simon TW; Baumann K; Hilpert F; Grube M; Schröder W; Burges A; Belau A; Hanker L; Kuhlmann JD
Clin Cancer Res; 2022 Nov; 28(21):4660-4668. PubMed ID: 36001383
[TBL] [Abstract][Full Text] [Related]
4. Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia.
Hulse RP; Beazley-Long N; Hua J; Kennedy H; Prager J; Bevan H; Qiu Y; Fernandes ES; Gammons MV; Ballmer-Hofer K; Gittenberger de Groot AC; Churchill AJ; Harper SJ; Brain SD; Bates DO; Donaldson LF
Neurobiol Dis; 2014 Nov; 71():245-59. PubMed ID: 25151644
[TBL] [Abstract][Full Text] [Related]
5. Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer.
Xu L; Chi C; Wang C; Zhang LM
Eur Rev Med Pharmacol Sci; 2014; 18(18):2687-92. PubMed ID: 25317804
[TBL] [Abstract][Full Text] [Related]
6. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer.
Hyodo I; Doi T; Endo H; Hosokawa Y; Nishikawa Y; Tanimizu M; Jinno K; Kotani Y
Eur J Cancer; 1998 Dec; 34(13):2041-5. PubMed ID: 10070308
[TBL] [Abstract][Full Text] [Related]
9. Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease.
Stevens M; Oltean S
Genes (Basel); 2018 Feb; 9(2):. PubMed ID: 29462869
[TBL] [Abstract][Full Text] [Related]
10. Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver mestastasis vascularity and volume.
Davies MM; Jonas SK; Kaur S; Allen-Mersh TG
Br J Cancer; 2000 Mar; 82(5):1004-8. PubMed ID: 10737380
[TBL] [Abstract][Full Text] [Related]
11. VEGF-A165b levels are reduced in breast cancer patients at primary diagnosis but increase after completion of cancer treatment.
Karsten MM; Beck MH; Rademacher A; Knabl J; Blohmer JU; Jückstock J; Radosa JC; Jank P; Rack B; Janni W
Sci Rep; 2020 Feb; 10(1):3635. PubMed ID: 32108136
[TBL] [Abstract][Full Text] [Related]
12. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis.
Cressey R; Wattananupong O; Lertprasertsuke N; Vinitketkumnuen U
BMC Cancer; 2005 Oct; 5():128. PubMed ID: 16202150
[TBL] [Abstract][Full Text] [Related]
13. Urinary and circulating levels of the anti-angiogenic isoform of vascular endothelial growth factor-A in patients with chronic kidney disease.
Kikuchi R; Yasuda Y; Nakatochi M; Shibata Y; Hara T; Suzuki A; Imaizumi T; Suzuki S; Ishii H; Takeshita K; Matsushita T; Maruyama S; Murohara T
Clin Chim Acta; 2017 Dec; 475():102-108. PubMed ID: 29055691
[TBL] [Abstract][Full Text] [Related]
14. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
15. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
[TBL] [Abstract][Full Text] [Related]
16. The role of VEGF-A165b in trophoblast survival.
Bills VL; Hamdollah-Zadeh M; Soothill PW; Harper SJ; Bates DO
BMC Pregnancy Childbirth; 2014 Aug; 14():278. PubMed ID: 25128406
[TBL] [Abstract][Full Text] [Related]
17. Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
Van Cutsem E; Paccard C; Chiron M; Tabernero J
Clin Cancer Res; 2020 Feb; 26(3):717-725. PubMed ID: 31727675
[TBL] [Abstract][Full Text] [Related]
18. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.
Suenaga M; Cao S; Zhang W; Yang D; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Soni S; Barzi A; Yamaguchi T; Lenz HJ
Int J Cancer; 2019 May; 144(10):2567-2577. PubMed ID: 30411783
[TBL] [Abstract][Full Text] [Related]
20. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
